Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.74 USD

8.74
541,902

-0.11 (-1.24%)

Updated May 20, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 253)

Industry: Medical - Drugs

Trades from $1

Balance Sheet

Research for TBPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 173 293 281 505 349
Receivables 14 16 22 11 10
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 17
Other Current Assets 62 85 36 17 4
Total Current Assets 250 393 338 533 379
Net Property & Equipment 14 16 13 13 10
Investments & Advances 68 13 5 12 42
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 3 6 2 11
Total Assets 375 469 409 560 441
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 3 7 5 9 6
Current Portion Long-Term Debt 17 19 10 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 38 76 58 46 57
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 12 32 43 0
Total Current Liabilities 59 124 112 99 63
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 7 34 4
Convertible Debt 228 227 226 225 224
Long-Term Debt 371 373 219 230 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 21 25 36
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 713 773 633 612 326
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,387 1,223 1,025 961 914
Retained Earnings -1,726 -1,527 -1,249 -1,012 -798
Other Equity 0 0 0 0 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -339 -304 -224 -52 115
Total Liabilities & Shareholder's Equity 375 469 409 560 441
Total Common Equity -339 -304 -224 -52 115
Shares Outstanding 73.70 63.90 56.70 55.40 54.10
Book Value Per Share -4.59 -4.75 -3.95 -0.93 2.13

Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Assets          
Cash & Equivalents 148 173 216 265 210
Receivables 12 14 14 12 12
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 45 62 67 56 71
Total Current Assets 205 250 297 333 293
Net Property & Equipment 13 14 16 17 17
Investments & Advances 94 68 45 36 19
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 4 4 2 3
Total Assets 355 375 403 429 375
Liabilities & Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Notes Payable 0 0 0 0 0
Accounts Payable 2 3 9 11 7
Current Portion Long-Term Debt 9 17 13 7 12
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 30 38 41 43 59
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 3 6 8
Total Current Liabilities 44 59 66 67 86
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 228 228 228 228 227
Long-Term Debt 384 371 376 375 375
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 3 2 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 707 713 727 730 748
Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,401 1,387 1,370 1,358 1,233
Retained Earnings -1,752 -1,726 -1,694 -1,659 -1,606
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -351 -339 -324 -300 -373
Total Liabilities & Shareholder's Equity 355 375 403 429 375
Total Common Equity -351 -339 -324 -300 -373
Shares Outstanding 75.90 73.70 73.70 73.40 65.20
Book Value Per Share -4.63 -4.59 -4.39 -4.09 -5.72